CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?
Top Page
CV Sciences
(OTC:CVSI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.03
▼(-67.78% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (sharp TTM revenue decline, ongoing losses, and negative/declining free cash flow) and bearish technical conditions (below key moving averages with negative MACD). Offsetting these, the latest earnings call indicates improving operations and guidance toward positive operating cash flow in H2 2026, though low cash levels and continued top-line pressure keep risk elevated.
Positive Factors
Improving gross margin via insourcing
Insourcing and lower product costs translated into a near-term gross margin lift. Greater in-house manufacturing control can sustainably lower COGS, reduce supplier risk, and support margin resilience as revenue fluctuates, improving the company’s path to durable profitability.
Negative Factors
Sustained top-line decline and falling units
Persistent revenue and unit volume declines signal structural demand headwinds in the CBD category. Over time, shrinking top-line impairs operating leverage, limits ability to absorb fixed costs, and can negate margin gains unless growth or meaningful stabilization is restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving gross margin via insourcing
Insourcing and lower product costs translated into a near-term gross margin lift. Greater in-house manufacturing control can sustainably lower COGS, reduce supplier risk, and support margin resilience as revenue fluctuates, improving the company’s path to durable profitability.
Read all positive factors
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.22M
Dividend YieldN/A
Average Volume (3M)246.65K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-12.61%
EPS Growth23.08%
CountryUS
Employees47
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding203,977,520
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit1.06
Enterprise Value/Ebitda-7.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. (CVSI) is a biotechnology company focused on the research, development, and commercialization of products derived from hemp extract, particularly those containing cannabidiol (CBD). Operating primarily in the wellness and pharmac...
How the Company Makes Money
CV Sciences primarily makes money by selling finished CBD wellness products and related consumer packaged goods. Revenue is generated from (1) wholesale/retail distribution, where the company sells products to retailers and distributors that then ...
CV Sciences Earnings Call Summary
Earnings Call Date:May 08, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.Positive Updates
Revenue Resilience Despite Headwinds
Revenue of $3.2M for Q1 2026, only down 3% sequentially from Q4 2025 and down 11% year-over-year, demonstrating resilience in a difficult operating and regulatory environment.
Negative Updates
Top-Line Pressure and Unit Sales Decline
Revenue declined 11% year-over-year and unit sales fell approximately 12%, indicating continued category pressure and softer demand across the CBD market.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Resilience Despite Headwinds
Revenue of $3.2M for Q1 2026, only down 3% sequentially from Q4 2025 and down 11% year-over-year, demonstrating resilience in a difficult operating and regulatory environment.
Read all positive updates
Company Guidance
The company guided that it is approaching cash‑flow breakeven and expects to generate positive operating cash flow in the second half of 2026, driven by continued cost reductions, in‑sourcing and synergies from recent acquisitions that are expected to materialize in H2 2026; key reported Q1 metrics supporting that path include revenue of $3.2M (down 3% sequential, 11% YoY), unit sales down 12%, gross margin 48.9% (vs. 50.5% in Q4 2025 and 46.0% in Q1 2025), operating expenses of $1.9M (≈13% lower YoY), adjusted EBITDA loss of $0.1M (improved from a $0.3M loss), operating loss of $0.3M (vs. ~$11k operating income prior year), net loss of $0.6M (vs. $0.1M), cash of ~$0.3M, positive operating cash flow of ~$0.1M (vs. ~$0.1M usage prior year), inventory of $3.9M (down from $4.1M), and a direct‑to‑consumer channel representing 44% of revenue; management also reiterated plans to launch multiple non‑cannabinoid products in 2026 (including the EMPOWR product with 20g protein and 5g creatine), expand select international markets, and pursue opportunities from the CMS BEI program (up to $500 per beneficiary annually, permitting eligible hemp‑derived CBD with up to 3 mg THC per serving), with broader patient adoption visibility expected later in 2026 and into 2027.CV Sciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.38M | 13.79M | 15.71M | 16.00M | 16.20M | 20.05M |
| Gross Profit | 6.66M | 6.75M | 7.17M | 7.08M | 5.55M | 8.62M |
| EBITDA | -950.00K | -562.00K | -1.86M | 3.85M | -5.66M | -14.00M |
| Net Income | -1.49M | -958.00K | -2.39M | 3.10M | -8.21M | -15.55M |
Balance Sheet | ||||||
| Total Assets | 6.72M | 6.96M | 7.93M | 26.35M | 12.74M | 18.07M |
| Cash, Cash Equivalents and Short-Term Investments | 309.00K | 278.00K | 454.00K | 1.32M | 611.00K | 1.38M |
| Total Debt | 1.49M | 1.61M | 779.00K | 442.00K | 1.53M | 922.00K |
| Total Liabilities | 5.22M | 5.49M | 6.13M | 23.44M | 13.51M | 14.52M |
| Stockholders Equity | 1.50M | 1.47M | 1.79M | 2.90M | -777.00K | 3.54M |
Cash Flow | ||||||
| Free Cash Flow | -297.00K | -516.00K | -879.00K | 2.25M | -1.89M | -7.52M |
| Operating Cash Flow | -225.00K | -407.00K | -861.00K | 2.25M | -1.89M | -7.49M |
| Investing Cash Flow | -72.00K | -109.00K | -28.00K | -156.00K | 0.00 | -35.00K |
| Financing Cash Flow | -211.00K | 337.00K | 32.00K | -1.39M | 1.12M | 4.37M |
CV Sciences Technical Analysis
Negative
0.09
Price Trends
0.03
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
42.48
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $42.12M | -2.39 | -122.57% | ― | -100.00% | 54.21% | |
47 Neutral | $7.99M | >-0.01 | -40.66% | ― | 2.00% | 94.31% | |
46 Neutral | $6.22M | -2.36 | -79.25% | ― | -12.61% | 23.08% | |
42 Neutral | $13.74M | -1.33 | -63.82% | ― | 29.75% | 37.35% | |
42 Neutral | $1.51M | -0.46 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
CVSI
CV Sciences
0.03
<0.01
20.00%
YCBD
cbdMD
0.76
-0.20
-20.83%
COSM
Cosmos Holdings
0.25
-0.20
-43.62%
IMCC
IM Cannabis Corp
0.24
-1.63
-87.06%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.52
-3.01
-46.10%
CV Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
CV Sciences Reports Q1 Results Amid Regulatory Headwinds
Neutral
May 14, 2026
On May 14, 2026, CV Sciences reported first-quarter 2026 results showing revenue of $3.2 million, down 11.4% year over year, as restrictive federal and state regulations weighed on sales volumes, though gross margin improved to 48.9%. The company ...
Business Operations and StrategyFinancial Disclosures
CV Sciences Reports 2025 Results and Profitability Improvements
Positive
Mar 26, 2026
CV Sciences reported its fiscal 2025 and fourth-quarter 2025 results on March 26, 2026, showing revenue declined to $13.8 million from $15.7 million in 2024, largely due to out-of-stock issues and restrictive regulations, even as 39% of annual net...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
CV Sciences Restructures Debt with New Convertible Note Deal
Positive
Mar 11, 2026
On March 4, 2026, CV Sciences, Inc. entered into an agreement with an institutional investor to amend and restate two existing secured promissory notes with an aggregate principal now increased by 20% to $2,256,000. The amended notes add a convers...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.